

(51) International Patent Classification:
C07K 16/18 (2006.01)(21) International Application Number:
PCT/US2015/033076(22) International Filing Date:
29 May 2015 (29.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/004,571 29 May 2014 (29.05.2014) US
62/008,229 5 June 2014 (05.06.2014) US
62/107,824 26 January 2015 (26.01.2015) US

(71) Applicant: MACROGENICS, INC. [US/US]; 9640 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: JOHNSON, Leslie, S.; 14411 Poplar Hill Road, Darnestown, MD 20874 (US). HUANG, Ling; 8210 Moorland Lane, Bethesda, MD 20817 (US). CHICHILI,

Gurunadh, Reddy; 13926 Lullaby Road, Germantown, MD 20874 (US). SHAH, Kalpana; 13013 Ethel Rose Way, Boyds, MD 20841 (US). LAM, Chia-Ying, Kao; 762 Bounty Drive #6209, Foster City, CA 94404 (US). BURKE, Stephen, James; 5306 Dove Drive, Mount Airy, MD 21771 (US). LIU, Liqin; 13515 Stonebridge Terrace, Germantown, MD 20874 (US). MOORE, Paul, A.; 7013 Old Gate Road, Bethesda, MD 20852 (US). BONVINI, Ezio; 11136 Powder Horn Drive, Potomac, MD 20854 (US). BARAT, Bhaswati; 15504 Villisca Terrace, Derwood, MD 20855 (US).

(74) Agents: AUERBACH, Jeffrey, I. et al.; Auerbachschrot LLC, 2200 Research Blvd., Suite 560, Rockville, MD 20850 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,

[Continued on next page]

(54) Title: TRI-SPECIFIC BINDING MOLECULES AND METHODS OF USE THEREOF




Figure 4A

(57) Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multichain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.



KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))